Hunter C. Smith's most recent trade in Rhythm Pharmaceuticals Inc. was a trade of 23,400 Common Stock done at an average price of $6.9 . Disclosure was reported to the exchange on May 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 30 May 2025 | 23,400 | 133,329 (0%) | 0% | 6.9 | 160,992 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2025 | 23,400 | 77,194 | - | - | Stock Options (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 61.52 per share. | 30 May 2025 | 18,993 | 109,929 (0%) | 0% | 61.5 | 1,168,495 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.93 per share. | 30 May 2025 | 4,407 | 128,922 (0%) | 0% | 60.9 | 268,515 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 62,500 | 62,500 | - | - | Stock Options (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 41,650 | 41,650 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 6,600 | 112,144 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 6,600 | 19,800 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 57.22 per share. | 14 Feb 2025 | 2,215 | 109,929 (0%) | 0% | 57.2 | 126,742 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.39 per share. | 12 Feb 2025 | 739 | 105,556 (0%) | 0% | 56.4 | 41,672 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.25 per share. | 12 Feb 2025 | 12 | 105,544 (0%) | 0% | 56.3 | 675 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 4,062 | 4,062 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 4,062 | 105,248 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 2,343 | 0 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 2,343 | 107,591 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 57.51 per share. | 09 Feb 2025 | 1,291 | 106,300 (0%) | 0% | 57.5 | 74,245 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 57.60 per share. | 09 Feb 2025 | 5 | 106,295 (0%) | 0% | 57.6 | 288 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 4,925 | 102,864 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 4,925 | 9,850 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 59.43 per share. | 01 Feb 2025 | 1,678 | 101,186 (0%) | 0% | 59.4 | 99,724 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.22 per share. | 19 Mar 2024 | 15,515 | 97,939 (0%) | 0% | 39.2 | 608,498 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Smith C. Hunter | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 80,400 | 80,400 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter Smith C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 33,750 | 113,454 (0%) | 0% | 0 | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Smith Hunter C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 26,400 | 26,400 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | C. Hunter Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,063 | 8,124 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Smith C. Hunter | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,063 | 79,278 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 2,344 | 81,622 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter Smith C. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 2,344 | 2,343 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 51.38 per share. | 09 Feb 2024 | 1,209 | 80,413 (0%) | 0% | 51.4 | 62,118 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter Smith C. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.82 per share. | 09 Feb 2024 | 709 | 79,704 (0%) | 0% | 49.8 | 35,322 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Smith Hunter C. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 4,925 | 76,831 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | C. Hunter Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 4,925 | 14,775 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Smith Hunter C. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.06 per share. | 01 Feb 2024 | 1,616 | 75,215 (0%) | 0% | 45.1 | 72,817 | Common Stock |
| Rhythm Pharmaceuticals Inc. | C. Smith Hunter | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 29 Dec 2023 | 10,500 | 71,906 (0%) | 0% | 6.9 | 72,240 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 10,500 | 100,594 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | C. Hunter Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2023 | 20,000 | 111,094 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter Smith C. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 05 Dec 2023 | 20,000 | 61,406 (0%) | 0% | 40 | 800,000 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Smith C. Hunter | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 05 Dec 2023 | 20,000 | 81,406 (0%) | 0% | 6.9 | 137,600 | Common Stock |
| Rhythm Pharmaceuticals Inc. | C. Smith Hunter | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2023 | 7,026 | 131,094 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | C. Hunter Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 05 Dec 2023 | 7,026 | 68,432 (0%) | 0% | 6.9 | 48,339 | Common Stock |
| Rhythm Pharmaceuticals Inc. | C. Hunter Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.06 per share. | 05 Dec 2023 | 7,026 | 61,406 (0%) | 0% | 35.1 | 246,360 | Common Stock |
| Aeglea BioTherapeutics Inc | Hunter C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 1,950,000 | 1,950,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 2,000 | 161,094 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 Jun 2023 | 2,000 | 61,406 (0%) | 0% | 6.9 | 13,760 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 2,344 | 60,108 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 2,344 | 4,687 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 11 Feb 2023 | 702 | 59,406 (0%) | 0% | 26.9 | 18,863 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.51 per share. | 09 Feb 2023 | 1,413 | 57,764 (0%) | 0% | 27.5 | 38,872 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 53,600 | 53,600 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 19,700 | 19,700 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Dec 2022 | 2,500 | 55,114 (0%) | 0% | 0 | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 25,000 | 0 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 25,000 | 65,161 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.08 per share. | 30 Jun 2022 | 7,547 | 57,614 (0%) | 0% | 4.1 | 30,792 | Common Stock |
| Aeglea BioTherapeutics Inc | Hunter C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 43,000 | 43,000 | - | - | Director Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 2,344 | 7,031 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 2,344 | 40,994 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 11 Feb 2022 | 833 | 40,161 (0%) | 0% | 6.1 | 5,081 | Common Stock |
| Aeglea BioTherapeutics Inc | Hunter C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2021 | 60,000 | 60,000 | - | - | Director Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 21 Apr 2021 | 5,000 | 38,650 (0%) | 0% | 6.9 | 34,400 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2021 | 5,000 | 163,094 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 56,250 | 56,250 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 9,375 | 9,375 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 19 Jan 2021 | 4,000 | 33,650 (0%) | 0% | 6.9 | 27,520 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 4,000 | 168,094 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Hunter C. Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |